<p>Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1</p>-Reference-Cited by-同舟云学术

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

Published:2020-06 Issue: Volume:Volume 13 Page:211-220
ISSN:1178-7023
Container-title:Clinical and Experimental Gastroenterology
language:en
Short-container-title:CEG

Author:

Loftus Jr Edward V^ORCID,Sands Bruce E^ORCID,Colombel Jean-Frédéric,Dotan Iris,Khalid Javaria Mona^ORCID,Tudor David,Geransar Parnia

Publisher

Informa UK Limited

Subject

Gastroenterology

Reference36 articles.

1. Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence

2. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

3. Inflammatory Bowel Disease

4. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

5. Ulcerative colitis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials;BMC Gastroenterology;2024-03-27

2. Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis;Therapeutic Advances in Gastroenterology;2024-01

3. Continuous clinical remission with biologics in ulcerative colitis: the ‘AURORA’ comparison study;European Journal of Gastroenterology & Hepatology;2022-09-23

4. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis;BMC Gastroenterology;2022-06-08

5. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis;Digestive and Liver Disease;2021-12